These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 35233792

  • 1. Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition.
    Vernon-Roberts A, Lopez RN, Frampton CM, Day AS.
    JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1535-1552. PubMed ID: 35233792
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of taurolidine-citrate in a cohort of patients with intestinal failure receiving home parenteral nutrition.
    Williams TJ, Moy N, Kaazan P, Callaghan G, Holtmann G, Martin N.
    JPEN J Parenter Enteral Nutr; 2024 Feb; 48(2):165-173. PubMed ID: 38062902
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition.
    Al-Amin AH, Sarveswaran J, Wood JM, Burke DA, Donnellan CF.
    J Vasc Access; 2013 Feb; 14(4):379-82. PubMed ID: 23817948
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Strategies to Reduce Catheter-Related Bloodstream Infections in Pediatric Patients Receiving Home Parenteral Nutrition: The Efficacy of Taurolidine-Citrate Prophylactic-Locking.
    Lambe C, Poisson C, Talbotec C, Goulet O.
    JPEN J Parenter Enteral Nutr; 2018 Aug; 42(6):1017-1025. PubMed ID: 29385236
    [Abstract] [Full Text] [Related]

  • 7. Use of Catheter Lock Solutions in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Individual-Patient Data Meta-Analysis.
    Wouters Y, Causevic E, Klek S, Groenewoud H, Wanten GJA.
    JPEN J Parenter Enteral Nutr; 2020 Sep; 44(7):1198-1209. PubMed ID: 31985068
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Taurolidine-related adverse events in patients on home parenteral nutrition frequently indicate catheter-related problems.
    Korzilius JW, Gillis VELM, Wouters Y, Wanten GJA.
    Clin Nutr; 2022 Oct; 41(10):2178-2184. PubMed ID: 36067590
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis.
    Nguyen T, Camins BC, Butler DA.
    Am J Ther; 2022 Oct; 31(4):e398-e409. PubMed ID: 38710029
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of home parenteral nutrition patients using taurolidine as catheter lock: A long-term cohort study.
    Wouters Y, Roosenboom B, Causevic E, Kievit W, Groenewoud H, Wanten GJA.
    Clin Nutr; 2019 Oct; 38(5):2210-2218. PubMed ID: 30292482
    [Abstract] [Full Text] [Related]

  • 16. Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine locks.
    Olthof ED, Rentenaar RJ, Rijs AJ, Wanten GJ.
    Clin Nutr; 2013 Aug; 32(4):538-42. PubMed ID: 23267744
    [Abstract] [Full Text] [Related]

  • 17. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition.
    Wouters Y, Theilla M, Singer P, Tribler S, Jeppesen PB, Pironi L, Vinter-Jensen L, Rasmussen HH, Rahman F, Wanten GJA.
    Aliment Pharmacol Ther; 2018 Aug; 48(4):410-422. PubMed ID: 29978597
    [Abstract] [Full Text] [Related]

  • 18. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
    Gudiol C, Nicolae S, Royo-Cebrecos C, Aguilar-Guisado M, Montero I, Martín-Gandul C, Perayre M, Berbel D, Encuentra M, Arnan M, Cisneros-Herreros JM, Carratalà J.
    Trials; 2018 May 02; 19(1):264. PubMed ID: 29720244
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.